April 18, 2024

Biosimilars Action Plan

To encourage innovation and competition in the market for biological products and facilitate the development of biosimilars and interchangeable biosimilars, FDA has developed the Biosimilars Action […]
April 18, 2024

Pharmaceutical Inspections and Compliance

FDA classifies inspections based on a company’s state of compliance as acceptable or unacceptable with respect to CGMP requirements: No action indicated (NAI) classification indicates a facility […]
April 17, 2024

Tainted Arthritis | Pain Products

FDA is notifying consumers of certain products promoted for arthritis and pain management that have been found to contain hidden ingredients and may pose a significant […]
April 17, 2024

Ossos-Sans contains hidden drug ingredients

[4-17-2024] The Food and Drug Administration is advising consumers not to purchase or use Ossos-Sans, a product promoted and sold for pain on various websites, including https://alnaturaleshop.com, […]
April 17, 2024

Regulatory Pharmaceutical Fellowship Program

Medication Safety Two-Year Medication Error Pharmacovigilance and Risk Management Fellowship provided by Butler University Fellowship dates: TBD, typical timeline shown below. Four months will be spent […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0